Citius Oncology, Inc. (CTOR) income statement
CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$0.55+0.01 (+2.36%)
Close on Nov 17, 2026Market cap $50.92MP/E –Yield –
Citius Oncology, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -109.5%
Financial strength
- Current ratio
- 0.73
- Debt to equity
- 0.16
- Debt to assets
- 5.7%
- Cash to current liabilities
- 28.2%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.26
- Dividend yield
- –
See a number that looks wrong?